Homepage | Lung Cancer

This site is intended only for healthcare professionals residing in Singapore

Log Out

Our medicines

Therapy areas

Explore content

Events

Materials

Videos

Let’s connect

Medical Information

Single Link

Know your EGFR

About NSCLC

Definition and staging of NSCLC

Prevalence and incidence of NSCLC

Molecular subtypes of NSCLC

Know your EGFR

Know your ALK

Heading

Example of description text sitting alongside header

Label

Link

Label

Link

Label

Link

Non-Small-Cell Lung Cancer (NSCLC)

Lung cancer continues to be a leading cause of cancer mortality worldwide,¹ impacting millions of people around the world. For patients diagnosed between 2011 and 2017 with NSCLC with distant metastases (SEER Stage), the 5-year survival rate was only 8%,² highlighting the importance of early diagnosis, optimized treatment options and successful management of adverse events to improve patients' quality of life. Find out more about the recent advances in this field and what you can do to improve outcomes for your patients.

Definition and staging of NSCLC

Learn more

Prevalence and incidence of NSCLC

Learn more

Molecular subtypes of NSCLC

Learn more

H3 (Mobile)

References

Global Cancer Observatory. Available here (accessed July 2022).

American Cancer Society. Lung cancer survival rates. Available here (accessed July 2022).

PP-LOR-SGP-0029/03MAR2023

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.